Screening and selection of bacteria inhibiting white spot syndrome virus infection to Litopenaeus vannamei

Functionality of probiotics on the resistance capacity of shrimp against white spot syndrome virus (WSSV)

Shrimp aquaculture is currently regarded as a significant commercial and food production sector due to its growing importance as a source of human-consumable protein, As shrimp farming has become more intensive, disease outbreaks have become more common, necessitating the overuse of antimicrobial drugs, which has had a number of unintended consequences. The white spot syndrome virus (WSSV) is now recognized as one of the world's most pervasive and potentially fatal diseases affecting shrimp. However, there is currently no cure to prevent the disease's uncontrolled incidence and spread. Probiotics are currently favoured over these antimicrobial substances because of their ability to stimulate disease resilience in shrimp farms by strengthening the immune systems naturally. Probiotics for bacterial infections such as vibriosis are well documented, whereas research is still required to identify the legitimate strains for viral diseases. The utilization of these probiotics as a therapy for and preventative measure against WSSV in shrimp farming is a cutting-edge method that has proven to be effective. Some probiotic strains, such as Bacillus spp, Lactobacillus, and Pediococcus pentosaceus, have been displayed to enhance the innate immunity of shrimp against WSSV, reduce viral load, increase digestibility and growth, and support the gut microbiome of the host in multiple investigations. The present review explores recent developments regarding the function of probiotics in shrimp, with a focus on their anti-WSSV activity.

Potential application of the probiotic Bacillus licheniformis as an adjuvant in the treatment of diseases in humans and animals: A systematic review

The use of Bacillus licheniformis as a probiotic has increased significantly in recent years. Published reports demonstrate that it provides multiple benefits for health. Although there are already studies in humans and is marketed, it is mostly used in the veterinary industry still. However, its benefits could be extrapolated to humans in future. This review addresses the application of B. licheniformis, its sporulation, mechanisms of action, and its role in the resolution, treatment, and prevention of different conditions and diseases. It focuses on scientific advances from 2016 to mid-2022 and emphasizes the most common diseases in the general population. Most of the 70% of published studies about the health benefits of B. licheniformis have been published from 2016 until now. The intake of B. licheniformis has been related to the effects of modulation of the intestinal microbiota, antimicrobial activity, growth promotion, anti-inflammatory and immunostimulatory effects, promotion of the regulation of the lipid profile, increase of neurotransmitters, and stress reduction, among others. These results provide novel possible applications of this and other probiotics in general. Although many benefits can be reported on a microorganism, the combination with others could provide a better effect. Further studies like this need to be done to understand the specific advantages of each probiotic and its strains and therefore achieve a better selection of them for a specific disease or disorder.